Company Says it will Seek Approval of Alzheimer’s Drug

UNDATED (AP) — The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer’s disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia.

The announcement Tuesday is a surprise because the company earlier this year stopped two studies of the drug when partial results suggested it was not working. The company now says a new analysis of more results suggest that the drug helped reduce a decline of thinking skills at the highest dose.

The drug, called aducanumab, aims to help the body clear harmful plaques from the brain. Cambridge, Massachusetts-based Biogen is developing it with a Japanese company, Eisai Co. Ltd.

Shares of Biogen soared 36 percent to $305 in pre-market trading Tuesday.

About Brian Merchant

Brian Merchant grew up in Central Massachusetts and now lives in South Dennis on the Cape. He has been part of the news team in the CapeCod.com NewsCenter since the spring of 2014. He studied radio broadcasting at the University of Tennessee.



CapeCod.com
737 West Main Street
Hyannis, MA 02601
Contact Us | Advertise Terms of Use 
Employment and EEO | Privacy